Control Bionics (ASX:CBL) Net Income (Continuing Operations): A$-6.50 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Control Bionics Net Income (Continuing Operations)?

Control Bionics ASX:CBL Net Income (Continuing Operations) is A$-6.50 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Control Bionics's Net Income (Continuing Operations) for the six months ended in Dec. 2025 was A$-3.61 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-6.50 Mil.

Control Bionics  (ASX:CBL) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Control Bionics Net Income (Continuing Operations) Related Terms

Control Bionics Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Control Bionics's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Control Bionics Net Income (Continuing Operations) Chart

Control Bionics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Net Income (Continuing Operations)
Get a 7-Day Free Trial -3.55 -6.10 -5.63 -5.91 -6.11

Control Bionics Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.19 -3.72 -3.22 -2.89 -3.61

Control Bionics Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-6.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of A$-6.50 Mil mean?
Control Bionics (ASX:CBL) has a Net Income (Continuing Operations) of A$-6.50 Mil as of Dec. 2025. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Control Bionics and its competitors.
Is Control Bionics' Net Income (Continuing Operations) too high?
Control Bionics' current Net Income (Continuing Operations) is A$-6.50 Mil.
How does Control Bionics' Net Income (Continuing Operations) compare to ABT and SYK?
Control Bionics' Net Income (Continuing Operations) of A$-6.50 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Medical Devices & Instruments company?
A good Net Income (Continuing Operations) depends on the Medical Devices & Instruments industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Control Bionics and its competitors. Control Bionics's current Net Income (Continuing Operations) is A$-6.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.06 — trading 100% above its estimated fair value. The current Net Income (Continuing Operations) is A$-6.50 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current Net Income (Continuing Operations) is A$-6.50 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Control Bionics Business Description

Address 11-13 Pearson Street, Level 4, Cremorne, VIC, AUS, 3121
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.